Status:

COMPLETED

Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients

Lead Sponsor:

COL George Peoples, MD, FACS

Collaborating Sponsors:

Uniformed Services University of the Health Sciences

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purposes of this study are the following: 1. To assess safety and document local and systemic toxicity to the peptide vaccine (E75) 2. To determine maximum tolerated dose (MTD) and optimal biolog...

Detailed Description

Breast cancer is the most common malignancy and second most common cause of cancer-specific death among women in the United States. Despite advances in the diagnosis and treatment of breast cancer, on...

Eligibility Criteria

Inclusion

  • HER2/neu expressing tumor
  • HLA-A2+ and/or HLA-A3+ to receive the vaccine. HLA-A2- and/or HLA-A3- patients will be eligible to be included in the control group.
  • Immunologically intact with a good performance status
  • Identified as being high or intermediate risk for recurrence
  • Without evidence of disease
  • Completion of all standard first-line therapies (but may still be on hormonal therapy)

Exclusion

  • Tumor does not express HER2/neu
  • Not HLA-A2+ and/or HLA-A3+
  • Anergic
  • Receiving immunosuppressive therapy
  • In poor health (Karnofsky \<60%, ECOG \>2 and Tbili \>1.5 and creatinine\>2)
  • Pregnant (beta HCG+)
  • Metastatic disease or have refused standard therapies
  • Patients enrolled in other experimental protocols may enroll to this study only with the permission of the other study PI.

Key Trial Info

Start Date :

July 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00841399

Start Date

July 1 2001

End Date

March 1 2013

Last Update

March 31 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Walter Reed National Military Medical Center

Bethesda, Maryland, United States, 20889

2

Windber Medical Center

Windber, Pennsylvania, United States, 15963

Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients | DecenTrialz